Going-concern and liquidity risk
The company disclosed substantial doubt about its ability to continue as a going concern due to operating losses and liquidity challenges.
- Scope
- Corporate funding and continuity of operations
- Materiality
- High
DBV Technologies S.A.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company developing Viaskin, an epicutaneous patch platform designed to deliver allergens through the skin. Its lead program, Viaskin Peanut, is being advanced for peanut allergy in children, with the company focused on late-stage clinical development, regulatory filings, and commercial readiness in the United States and Europe.
−2 556,2 %
−2 607,3 %
+35,8 %
3.67
3.67
| % | |
|---|---|
| Viaskin Peanut program | 70% Lead product candidate for peanut allergy treatment using an epicutaneous patch. |
| Viaskin platform development | 15% Broader patch-based allergy immunotherapy technology and related pipeline work. |
| Clinical and regulatory activities | 10% Clinical trials, FDA/EMA interactions, and BLA/MAA preparation work. |
| Manufacturing and supply readiness | 5% Third-party manufacturing, quality control, and pre-commercial supply commitments. |
DBV does not sell a broad commercial product portfolio today; its primary end customers are patients with peanut...
- Peanut allergy patients and caregiversprimary
Families seeking a non-oral immunotherapy option for peanut allergy, especially pediatric patients targeted by Viaskin Peanut.
- Allergy specialists and pediatric physiciansprimary
Clinicians who would prescribe the patch if approved and drive adoption through treatment protocols.
- Regulators and health authoritiesprimary
FDA and EMA review the clinical package, safety data, and manufacturing readiness before approval.
- Clinical trial sites and investigatorssecondary
Hospitals and research centers that enroll patients and generate efficacy/safety evidence.
- Manufacturing and supply partnerssecondary
Third-party API and device manufacturers that enable clinical supply and future commercialization.
The company is operationally split between the United States and Europe, with a primary U.S...
- •Primary U.S. office in Warren, New Jersey
- •Additional North American facilities support U.S. operations
- •Viaskin Peanut API is manufactured in France
- •Critical raw materials and lab inputs are sourced largely from Europe
- •U.S. and EU regulatory paths drive development and launch planning
DBV’s strategy is to complete late-stage development of Viaskin Peanut, secure regulatory approval, and prepare for a U...
01
Complete late-stage clinical developmentshort-term
Positive pivotal data is needed to support regulatory submissions and commercial value creation.
02
Prepare regulatory filingsshort-term
BLA and potential EU submission are the gatekeepers to commercialization.
03
Secure manufacturing and supply chain readinessmedium-term
Commercial launch requires reliable third-party production and inventory availability.
04
Maintain liquidity through financingshort-term
The company is still pre-commercial and needs external capital to fund operations.
DBV remains a pre-commercial biotech with substantial going-concern risk, so its value depends heavily on clinical...
Clinical development failure
Viaskin Peanut depends on positive pivotal and supporting study results to justify filing and approval.
- Scope
- VITESSE, COMFORT Toddlers, and related studies
- Materiality
- High
Regulatory approval risk
The company needs FDA and potentially EMA acceptance of its clinical package and manufacturing readiness.
- Scope
- BLA and MAA submissions
- Materiality
- High
Third-party manufacturing dependence
DBV does not own manufacturing facilities and relies on external suppliers for API and patch production.
- Scope
- Sanofi supply chain and non-U.S. vendors
- Materiality
- High
Dilution from financing activities
ATM sales and warrant exercises can fund operations but may dilute existing shareholders.
- Scope
- Equity issuance and warrant overhang
- Materiality
- High
Tariffs and trade restrictions
Cross-border sourcing of API, raw materials, and lab inputs could raise costs and disrupt timelines.
- Scope
- France, Europe, and other non-U.S. sourcing
- Materiality
- Medium
Research and development expense recognition
Affects operating loss and comparability across periods
Supply agreement commitments
Can affect liabilities, R&D expense, and cash needs
Going-concern disclosure
Important for liquidity analysis and valuation
Equity financing and warrant accounting
Dilution and cash runway analysis
Lease accounting and relocation costs
Affects G&A expense and cash flow
: 28.4.2026